A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the management of type 2 diabetes (T2DM). Recent case reports have raised concerns about a potential association between semaglutide use and the development of no…
BACKGROUND: Weight management remains a significant challenge for patients with class II-III obesity, even after metabolic bariatric surgery (MBS). This study aimed to investigate the association between early, short-term adjunctive semaglutide thera…
BACKGROUND: Statin product labels (eg, Summaries of Product Characteristics [SmPCs]) list certain adverse outcomes as potential treatment-related effects based mainly on non-randomised and non-blinded studies, which might be subject to bias. We aimed…
INTRODUCTION: Type 2 diabetes mellitus (T2DM) can lead to structural pancreatic changes potentially predisposing to acute pancreatitis (AP), increasing morbidity and mortality. Scarce data exist on the outcomes of AP in patients with T2DM who are tak…
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are well-known medications commonly prescribed for type 2 diabetes management and pharmacologic management of obesity. While GLP-1 RAs have many positive effects on glycemic control and cardiovasc…
BACKGROUND: While glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor/GIP agonists (GLPs) have revolutionized the treatment of obesity, national data shows Black patients, Hispanic patients, and patients of lower socio…
OBJECTIVES: Temporal trends in exposure are a common source of bias in the case-crossover design. We evaluated four different estimators of the exposure odds ratio (OR) that adjust for such trends. METHODS: In a simulation study, we simulated 1 milli…
This study repurposes the Bowman-Birk inhibitor (BBI), traditionally viewed as an antinutritional factor for its protease inhibition, as a protective agent for peptide therapeutics. We co-encapsulated BBI with semaglutide in hydrogel beads to orchest…
AIMS: Published literature has raised concerns regarding a causal association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk…
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly common globally and is associated with significant morbidity and mortality, necessitating effective treatments to stop its progression. Multiple pharmacologic treatme…
BACKGROUND: The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus. M…
Long-term high-fat diets (HFD) induce obesity, neuroinflammation, and cognitive decline, increasing Alzheimer's disease (AD) risk. This study explores whether Semaglutide, a GLP-1 receptor agonist, mitigates these effects by modulating microglia via…
BACKGROUND/AIMS: Non-invasive test (NIT)-based assessment of eligibility and treatment response with semaglutide is needed to inform clinical practice guidance. Therefore, utilising a randomised, placebo-controlled study design, we evaluated the util…
BACKGROUND: Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for sever…
OBJECTIVE: This study aimed to evaluate whether reduced-frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy. METHO…
The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weigh…